文献速递骨软组织肉瘤与黑色素瘤

荷兰BRAF突变晚期黑色素瘤治疗序列的成本效果:基于健康经济模型的研究

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.
PubMed 文献 · Eur J Cancer · 2024-10-16

本研究从社会视角评估荷兰BRAF突变晚期黑色素瘤的21种治疗序列的成本效果,采用半马尔可夫模型和荷兰黑色素瘤治疗登记处真实世界数据。

要点

  • 治疗序列中首个治疗及治疗持续时间假设对成本效果结果有实质性影响。

核心结论

  • 在不同成本效果阈值下,这些ICER可被认为具有成本效果。

研究设计与样本

  • 采用半马尔可夫模型,时间范围为终身,评估21种治疗序列的成本效果。
  • 使用荷兰黑色素瘤治疗登记处的真实世界数据估计进展时间、下一治疗时间和死亡。
  • 效用值、医院成本、院外医疗成本、患者和家庭成本及生产力成本均源自荷兰黑色素瘤治疗登记处。
  • 药物成本基于推荐剂量和治疗持续时间估算。
  • 增量成本效果比表示为每获得一个QALY的增量成本。

主要发现

  • 治疗序列中首个治疗及治疗持续时间假设对成本效果结果有实质性影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to evaluate the cost-effectiveness of treatment sequences for patients with advanced melanoma with a BRAF mutation in the Netherlands from a societal perspective. METHODS: A semi-Markov model with a life-time horizon has been used to evaluate cost-effectiveness of 21 treatment sequences. Real-world data from the Dutch Melanoma Treatment Registry (DMTR) were used to estimate time to progression, next treatment and death. Utilities by health state as well as hospital costs, health care costs outside the hospital, patient and family costs and productivity costs were also derived from the DMTR. Drug costs were estimated based on the recommended dose and duration of treatment. Incremental cost-effectiveness ratios (ICERs) were presented as incremental costs per QALY gained. RESULTS: Health benefits of treatment sequences consisting of targeted therapies and immunotherapies vary between 2.3 and 5.8 QALYs gained per patient when compared to chemotherapy. The increase in costs varies between €112,000 and €383,000. The efficiency frontier consists of nivolumab in the first line followed by ipilimumab in the second line (ICERs of €42,000/QALY and €44,000/QALY), nivolumab in the first line followed by encorafenib plus binimetinib in the second line (ICERs of €71,000/QALY and €68,000/QALY) and nivolumab plus ipilimumab in the first line followed by encorafenib plus binimetinib in the second line (ICERs of €74,000/QALY and €76,000/QALY). The first treatment given within a sequence as well as assumptions regarding treatment duration have a substantial impact on cost-effectiveness outcomes. CONCLUSION: The ICERs can be considered cost-effective at different cost-effectiveness thresholds.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Blommestein HM, de Groot S, Leeneman B, et al. Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model. Eur J Cancer. 2024. PMID: 39914026. doi:10.1016/j.ejca.2024.115071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。